PJ-68
PJ-68 is a selective PRMT5 inhibitor (IC50 = 517 nM). PJ-68 reduces KLF5 methylation, stability, and downstream target gene expression. PJ-68 induces Apoptosis, inhibits self-renewal capacity, blocks the Wnt/β-catenin signaling pathway by reducing DVL3 expression, and decreases BCR-ABL mRNA and protein levels. PJ-68 serves as a Ligand for Target Protein for PROTAC for the synthesis of PRMT5 PROTAC degraders, such as YZ-17 (HY-189213). PJ-68 inhibits the growth of basal-like breast cancer. PJ-68 prolongs the survival of CML mice. PJ-68 is used for research on basal-like breast cancer and chronic myeloid leukemia.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 352544-59-3
- Formel: C25H26N2
- Molecular Weight:354.49
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Alle Histone Methyltransferase Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
PRMT5 517 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCC1806 | IC50 |
5.3 μM
|
Antiproliferative activity against human HCC1806 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay.
Antiproliferative activity against human HCC1806 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay.
|
42566881 |
| HCC1937 | IC50 |
4.6 μM
|
Antiproliferative activity against human HCC1937 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay.
Antiproliferative activity against human HCC1937 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay.
|
42566881 |
In Vitro
PJ-68 (1-5 μM; 48 h) shows moderate antiproliferative activity against HCC1806 cells[1].
PJ-68 (10-50 μM) specifically inhibits PRMT5 methyltransferase activity and reduces BCR-ABL protein levels in K562 cells[2].
PJ-68 inhibits BCR-ABL gene transcription in K562 cells[2].
PJ-68 inhibits the transcription of the DVL3 gene in K562 cells[2].
PJ-68 reduces the enrichment of PRMT5 at the p15INK4B promoter in K562 cells[2].
PJ-68 (25.0 μM; 1 week) inhibits LTC-IC capacity in CML BM cells, and its combination with IM enhances this effect[2].
PJ-68 reduces H3R2SDM levels in K562 and CML CD34+ cells[2].
PJ-68 increases p15INK4B mRNA levels in K562 and CML CD34+ cells[2].
PJ-68 (0-6.0 μM; 24 h) does not significantly inhibit PRMT5-mediated sDMA modification in HCC1806 cells at concentrations up to 6 μM[1].
PJ-68 is a potent and selective inhibitor of PRMT5 methyltransferase activity with an IC50 of 517 nM[2].
PJ-68 inhibits PRMT5-mediated KLF5 methylation in cell-free in vitro methylation assays[3].
PJ-68 (5 μM; 6 h) decreases KLF5-WT protein levels in HEK293T cells, but does not decrease KLF5-R57K protein levels[3].
PJ-68 reduces the recruitment of PRMT5 and its epigenetic marks to the Mir203 promoter in K562 cells[2].
PJ-68 (25.0 μM; 96 h) selectively induces apoptosis in quiescent CML LSCs compared with NBM CD34+ cells[2].
PJ-68 increases the expression of cell cycle inhibitors p15INK4B and p27KIP1 in CML CD34+ cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HCC1806
-
Concentration:1 μM; 5 μM
-
Incubation Time:48 h
-
Result:Inhibited cell viability by 10.6% at 1 μM.
Inhibited cell viability by 40.7% at 5 μM.
-
Cell Line:HCC1806
-
Concentration:0; 0.5; 1.0; 2.0; 4.0; 6.0 μM
-
Incubation Time:24 h
-
Result:Did not significantly reduce sDMA levels at 6 μM.
In Vivo
PJ-68 (20-40 mg/kg; i.p.; daily; 3 weeks) significantly inhibits breast tumor growth in vivo in a dose-dependent manner by decreasing KLF5 and its downstream target proteins[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (6- to 8-week-old male donors and female recipients; retroviral BCR-ABL-driven CML model)[2]
-
Dosage:25 mg/kg/d and 50 mg/kg/d
-
Administration:i.p.; for 2 weeks
-
Result:Significantly prolonged survival of CML mice.
Extended survival further when combined with IM compared with each agent alone.
Did not observe splenomegaly in treated mice.
Significantly reduced the proportion of BCR-ABL-expressing (GFP+) leukemia cells and myeloid cells (Gr-1+ Mac-1+) in BM.
Markedly decreased the proportion of LSK cells, LT-HSCs, and ST-HSCs, as well as GMP and CMP in BM cells.
-
Animal Model:C57BL/6 (WT recipient mice; limiting dilution secondary transplantation of CML BM cells)[2]
-
Dosage:25 mg/kg/d and 50 mg/kg/d
-
Administration:i.p.; for 2 weeks (administered to primary CML mice prior to BM harvest)
-
Result:Greatly decreased the engraftment of GFP+ cells and the frequency of CML stem cells in secondary recipients.
Showed LT-HSC frequency of 1/1,437,773 for treated mice versus 1/223,325 for control and 1/426,051 for IM.
Decreased LT-HSC frequency to 1/3,283,885 when combined with IM.
-
Animal Model:Nude mice (female, 7 weeks old, HCC1806 cell-derived xenografts in mammary fat pads)[3]
-
Dosage:20-40 mg/kg
-
Administration:i.p.; daily; 3 weeks
-
Result:Inhibited tumor growth in a dose-dependent manner.
Decreased tumor weights following sacrifice.
Did not cause statistical differences in body weight among dose groups.
Decreased protein levels of KLF5 and its targets in primary tumor samples in a dose-dependent manner.
Chemical Information
-
CAS. Nr. 352544-59-3
-
Molecular Weight 354.49
-
Formel C25H26N2
-
SMILES
CCN1C2=C(C3=C1C=CC=C3)C=C(CNC4CCCC5=C4C=CC=C5)C=C2
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
RT-PCR
Reverse transcription technology uses RNA as a template to synthesize DNA. RT-PCR is simple, specific and sensitive, and can be used to detect gene expression levels and expression differences in cells; detect RNA virus content; clone cDNA sequences of specific genes.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Detection of Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
hPSC maintenance and expansion
This protocol maintains and expands human pluripotent stem cells under feeder-free, chemically defined conditions using E8 medium and vitronectin-coated culture surfaces; the readout is sustained adherent colony growth with undifferentiated morphology and retained pluripotency-marker expression during serial passaging. E8-based hPSC culture relies on defined soluble factors and matrix-dependent adhesion rather than feeder cells; vitronectin supports hPSC attachment through integrin-mediated interactions, and EDTA passaging dissociates colonies as small aggregates without enzymatic digestion, centrifugation, or routine ROCK-inhibitor treatment.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Real Time qPCR (Q-PCR)
Real-time quantitative PCR (qPCR) quantifies an amplifiable nucleic-acid target by monitoring fluorescence during PCR cycling rather than measuring product only after amplification. The increase in fluorescence tracks accumulation of PCR product, and the quantification cycle (Cq; historically also Ct/CP) is related to the initial amount of target: samples containing more starting target generally reach the defined fluorescence threshold in fewer cycles.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)